Recruitment and retention of the participants in clinical trials: Challenges and solutions

Abstract

Drug development is a tedious and expensive procedure and it takes roughly 10 to 15 years to take a potential treatment from bench to bedside and costs the pharmaceutical companies as much as USD ~2 billion for the process. Delay in investigator-initiated studies can cause financial loss to grant providers (either public or private) and investigator's reputation may also be at stake. Participant recruitment and retention are two major bottlenecks in conducting clinical trials and contribute vastly to the delays. They are essential for both scientific validity of the clinical study and economic reasons. Thus, issues in recruitment and retention should be addressed and minimized. A proper recruitment and retention plan incorporating adequate communication between all stakeholders will eventually avoid the delays in drug development and make treatments available to the consumer at an earlier date and at a more affordable price. Awareness of challenges and reviewing strategies that can optimise recruitment and retention will facilitate drug development. The article gives a first-person perspective on challenges and proposed solutions from an experienced clinical study centre in a tertiary care hospital.

The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials

“…Reducing the intensity of monitoring also reduces the inconvenience of traveling, which in turn helps address existing issues with patient retention in clinical trials. Patient drop-out and insufficient recruitment are often the cause of trials failing to complete accrual within the study period [ 61 ]. This is frustrating from a clinical perspective, as it prolongs the approval of beneficial therapies to reach a wider patient population.…”

The role of community advisory boards in community-based HIV clinical trials: a qualitative study from Tanzania

“…This in turn easy the recruitment process by making sure potential participants are timely located and enrolled into HIV clinical trials. It has been reported that delays (from bench to bedside use of the investigational product) encountered in most clinical trials are attributed to faults in the recruitment process, and the way out of this, is to equally involve all stakeholders prior to recruitment [ 32 ]. For that reason, CAB members should not be left out in the recruitment process, instead, are to be treated as equal partners (their opinion matters) when preparing a recruitment plan.…”

Role of artificial intelligence in peptide vaccine design against RNA viruses

“…It can analyze a large amount of clinical records of patients to determine their eligibility for a given study. Recruitment of volunteers is one of the many bottlenecks in conducting clinical trials [ 122 ]. It is often the most time-consuming and expensive step.…”